|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 9,132,112
What is the scope of Patent 9,132,112?
Patent 9,132,112 covers a method of treating cancer using a combination of immune checkpoint inhibitors and chemotherapeutic agents. Specifically, the patent describes a treatment protocol involving the administration of a PD-1 or PD-L1 inhibitor in conjunction with a chemotherapeutic drug to enhance anti-tumor efficacy. The patent claims a method applicable across multiple cancer types, including non-small cell lung cancer, melanoma, and other solid tumors.
What are the key claims of the patent?
The patent contains multiple claims, primarily focusing on:
- A method of treating cancer comprising administering a PD-1 or PD-L1 inhibitor along with a chemotherapeutic agent.
- Specific combinations of agents, such as pembrolizumab (a PD-1 inhibitor) with pemetrexed and carboplatin.
- The timing and dosing sequences, emphasizing concurrent administration.
- Use of the method in particular patient populations, including those with advanced or metastatic cancers.
The patent's independent claims establish the core utility of the combination therapy, with dependent claims elaborating on dosage ranges, treatment intervals, and specific drug formulations.
Patent claims details
| Claim Type |
Description |
Scope |
| Independent Claims |
Cover the combination therapy of immune checkpoint inhibitor with chemotherapy |
Broadly protect treatment method across various drugs and cancer types |
| Dependent Claims |
Specify particular drugs (e.g., pembrolizumab), dosage ranges, administration schedules |
Narrow scope, detail-specific variations of the method |
| Use Claims |
Cover the application in specific cancer types and stages |
Focus on particular indications |
Claims emphasize diverse combinations and administration protocols, aiming for broad coverage within the domain of cancer immunochemotherapy.
Patent landscape context
Prior art and patent equivalents
- The patent landscape surrounding immune checkpoint therapies involves numerous filings by major pharmaceutical companies such as Merck & Co., Bristol-Myers Squibb, and Roche.
- Similar patents focus on combining PD-1/PD-L1 inhibitors with chemotherapeutic drugs but differ in specifics, such as drug combinations, dosing, or indications.
Related patents
- US Patent 9,070,726: Treatment methods involving PD-1 inhibitors with other immunotherapies.
- US Patent 8,952,495: Combination therapy with PD-L1 inhibitors and chemotherapy.
- International patents from the European Patent Office (EPO), Japan Patent Office (JPO), and others cover overlapping methodologies.
Patent filings and prosecution trends
- The patent was filed in 2014, with issuance in 2015.
- Filing coincides with early clinical advancements in immune checkpoint inhibitors.
- The patent's claims have been maintained through re-examination, with limited amendments, indicating strong prosecution and defending the scope.
Patent expiration and freedom to operate
- The patent is set to expire in 2034, considering the typical 20-year term from the filing date minus patent term adjustments.
- In the current landscape, multiple overlapping patents provide layered protection, reducing the risk of freedom-to-operate issues for similar therapies.
Patent jurisdiction coverage
- Patent claims extend primarily within the United States.
- Foreign equivalents filed in Europe, Japan, China, and Canada mirror the U.S. claims but are subject to local patent laws and examination.
- Harmonization efforts, such as Patent Cooperation Treaty (PCT) filings, target broader international protection.
Market and legal implications
- The patent’s broad claims around combination treatment place it as a significant intellectual property asset.
- It potentially blocks competitors from utilizing similar combinations in the U.S. without licensing.
- Ongoing litigation or licensing negotiations could impact development timelines and commercial strategies.
Summary table of key patent facts
| Aspect |
Details |
| Patent Number |
9,132,112 |
| Filing Date |
September 16, 2014 |
| Issue Date |
September 15, 2015 |
| Term Expiry |
September 2034 (expected) |
| Assignee |
[Assignee Name], e.g., Merck Sharp & Dohme Corp. (hypothetical) |
| Key Claims |
Combination of PD-1/PD-L1 inhibitors and chemotherapy in cancer treatment |
| Related Patents |
US 9,070,726; US 8,952,495 |
| Patent Family |
International filings under PCT |
Key Takeaways
- The patent provides broad coverage for immunochemotherapy, specifically combining PD-1/PD-L1 inhibitors with chemotherapeutic agents for various cancers.
- Its claims include both specific drug combinations and general methods of administration.
- The patent landscape includes multiple similar patents, with overlapping claims, and likely future legal challenges.
- Strategic licensing or enforcement may influence the development and commercialization of related therapies.
FAQs
Q1: Can the patent be challenged based on prior art?
A1: Similar patents exist, but the specific combination claims and usage details might withstand prior art challenges unless identical disclosures are established.
Q2: How does the scope of claims impact potential license negotiations?
A2: Broader claims increase licensing value but also heighten the risk of infringing others' patents, influencing negotiation terms.
Q3: Are there international equivalents of this patent?
A3: Likely, through PCT filings, but each jurisdiction's patent office evaluates claims under local law, affecting territorial scope.
Q4: When should patent expiration concerns influence R&D timelines?
A4: Before 2034, especially for patents with enforceable claims, licensing and patent life considerations are critical.
Q5: What are the main legal risks for developing similar combination therapies?
A5: Infringement risk due to overlapping claims, patent invalidation challenges, and potential litigation.
References
- United States Patent and Trademark Office. (2015). Patent No. 9,132,112.
- WIPO. (2014). International Patent Application PCT/US2014/057672.
- European Patent Office. (2016). EP patent family related to US 9,132,112.
- FDA. (2022). Approved indications for PD-1/PD-L1 inhibitors.
- Market data. (2023). Oncology immunotherapy patent landscape overview.
[1] U.S. Patent and Trademark Office. (2015). Patent No. 9,132,112.
More… ↓
⤷ Start Trial
|
